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Abbreviations 
CCL  chemokine ligand 
CD  cluster of differentiation 
DC  dendritic cell(s) 
cDC  conventional dendritic cells 
EGF  epidermal growth factor 
FcεRIα high affinity IgE receptor alpha chain 
IFN  interferon 
IL  interleukin  
IRF  interferon regulatory factor 
mDC  myeloid dendritic cells 
pDC  plasmacytoid dendritic cells 
PD-L1  programmed death-ligand 1 
Th  T helper cell 
TSLP  thymic stromal lymphopoietin 
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Abstract 
Dendritic cells (DC) are potent antigen presenting cells. Because of their particular ability to 
initiate and regulate cell mediated and humoral immune responses, there is considerable 
interest in the role that DC play in the pathogenesis of various lung diseases, especially those 
in which there is an excessive immune response to specific antigens (as in asthma) or a 
deficient immune response (as in lung cancer). A number of DC subpopulations have been 
defined in the lungs including myeloid or conventional DC that initiate T-cell immunity and 
antibody production, and plasmacytoid DC that have an important role in anti-viral immunity 
and immune tolerance. Though an extensive body of literature has documented the role that 
DC play in experimental models of lung disease, this review will highlight recent advances in 
our understanding of DC function in human disease, including asthma, COPD, anti-microbial 
immunity and lung cancer. The future is likely to see new approaches whereby antigens and 
small molecules are targeted to receptors on particular DC subpopulations in order to modify 
pulmonary immune responses. 
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Introduction 
Dendritic cells (DC) are potent antigen presenting cells with key roles in the initiation 
and regulation of immune responses 1-3. In the respiratory tract, they constantly sample 
inhaled antigens from the airway and alveolar epithelial surfaces, before migrating to regional 
lymph nodes where they present processed peptides to antigen specific T-cells.  DC are 
unique in their capacity to activate naïve T-cells and initiate primary immune responses in 
lymph nodes, and also play a central role in reactivating memory T-cell responses in the lungs.  
However, DC are far more than a passive conduit for delivering antigens to lymph node T 
cells. They are exquisitely sensitive to environmental signals, be they derived from microbes, 
allergens, pollutants or the products of tissue damage. DC are responsive to ‘pathogen 
associated molecular patterns’ and ‘damage associated molecular patterns’ and this markedly 
alters the signals they provide to T-cells. Similarly, airborne pollutants such as diesel exhaust 
particles can alter DC function directly 4, or via interactions with airway epithelial cells 5.  DC-
derived signals regulate both the degree of T-cell activation, and the nature or ‘flavour’ of the 
immune response e.g. Th1, Th2, Th17, B-cell help or immune regulation.  DC can therefore be 
viewed as a finely tuned mechanism for integrating and transferring information from the 
lung to regional lymph nodes. In health, the ensuing immune response is appropriate to the 
type of pathogen and the presence or absence of tissue damage, though this is often perturbed 
in various lung diseases.  
 
DC subpopulations 
Several DC subpopulations have been defined 2,3, a fact that often seem bewildering to 
the non-expert, especially when the markers used to define DC differ between humans and 
mice. DC are broadly divided into myeloid DC (mDC), usually now referred to as conventional 
DC (cDC), and plasmacytoid DC (pDC). Within the respiratory tract, cDC form dense networks 
throughout the epithelium of large conducting airways, bronchioles, alveoli and interstitial 
space. Detailed analyzes of murine lungs have revealed that at least two cDC subsets are 
present in steady state; these differ in function and anatomical location as reviewed recently 
by others 2,3. The first subset of cDC express the integrin CD103, but lack CD11b and are 
intimately associated with the respiratory epithelium where they project their dendrites 
between epithelial cells, allowing them to directly sample airway luminal contents. CD103+ 
DC are dependent on the transcription factor interferon regulatory factor (IRF)-8 for their 
development, and are adept at taking up dead or damaged cells and presenting viral antigens 
to CD8 T-cells 2,3. The equivalent cDC subset in human lungs expresses CD141 (BDCA-3) and 
the C-type lectin CLEC9A. The second subset of lung cDC are identified in mice by CD11b 
expression and in humans by CD1c (BDCA-1): these are located beneath the basement 
membrane of the conducting airways and are dependent on the transcription factor IRF4 for 
their development. There is good evidence that CD103+ DC are biased toward induction of 
Th1 responses, whereas CD11b DC preferentially induce Th2 or Th17 responses, though this 
may vary according to the experimental model and type of antigen 2,3. In the setting of 
inflammation and injury, a third subset of ‘monocyte derived DC’ are rapidly recruited to the 
lungs. A recently published study employed an elegant technique to distinguish tissue 
resident DC in human lungs from DC present in the vascular lumen 6. The authors were able to 
define multiple myeloid subsets in lungs and draining lymph nodes including pulmonary DC 
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co-expressing CD1a and CD1c, and a variety of monocyte derived subpopulations including 
CD141+ DC 6. 
pDC are best characterized by their ability to synthesize prolific amounts of interferon 
(IFN) in response to virus infections 7. It is estimated that pDCs dedicate as much as 60% of 
their transcriptome to type I IFN production 8 and can release 100-fold more IFNα than any 
other known cell type 9. Even though pDC appear to be fully developed when they exit the 
bone marrow, they are relatively inefficient at presenting antigens to T-cells and seem to play 
an important role in tolerance induction 10, probably via induction of regulatory T-cells 11. In 
mice, pDC depletion induces a Th2 response and immunopathology following RSV infection 12, 
while our own studies have shown that pDC from healthy people inhibit Th2 responses 
induced by rhinoviruses 13. This regulatory mechanism may be lost in asthma. In humans, pDC 
are identified by surface markers such as BDCA-2 (CD303, a C-type lectin), BDCA-4 (CD304 or 
neuropilin-1), immunoglobulin-like transcript 7 (ILT7), and the IL-3 receptor-α chain 
(CD123) 7.   
 
Asthma 
Numerous studies have documented the involvement of DC populations in human 
asthma. The following discussion highlights key recent findings. It has been known for some 
time that increased numbers of airway mucosal DC are present in asthma. Initial studies 
utilized endobronchial biopsies and bronchoalveolar lavage (BAL), but it is now clear that 
airway DC can also be identified and characterized with induced sputum from adults 14,15 and 
children 16. In fatal asthma there is a higher density of DC in the outer wall of the large airways 
than in control subjects who died of non-pulmonary causes 17. These DC express factor XIIIa 
and are likely to have differentiated from recruited monocytes 17.  In people with allergic 
asthma, allergen inhalation has proved an effective method for studying the dynamics of DC 
migration, as it induces increased numbers of sputum cDC, including both CD11c+ and 
CD141+ subsets 14,18. Allergen challenge also increases numbers of bone marrow cDC, 
upregulating TSLP receptor but not IL-33 receptor on bone marrow DC, and primes bone 
marrow progenitors to differentiate into DC in response to haemopoietic growth factors 19. 
Studies in experimental asthma models have shown that airway derived prostaglandins can 
exert long lived immunomodulatory effects on DC progenitors in bone marrow 20, though 
whether this also occurs in persistent human asthma has yet to be determined. 
 
In asthma, airway cDC express ligands and receptors involved in type 2 inflammation. 
Thus, sputum cDC from people with mild asthma show higher expression of the Th2 
promoting costimulatory molecule OX40L and the chemokine CCL17 than sputum cDC from 
healthy control subjects, in conjunction with TSLP and IL-33 expression in airway epithelial 
cells 21. Allergen inhalation leads to higher IL-25 receptor (IL-17RB) expression on sputum 
cDC and pDC 22. The fact that IL-25 receptor is also upregulated on blood cDC and pDC 
suggests that allergen inhalation may be enhancing IL-25 receptor expression in bone 
marrow. People with allergic asthma also have a higher proportion of TSLP receptor 
expressing cDC in the blood and bronchial mucosa, and are more responsive to the Th2 
promoting effects of TSLP than healthy controls 23.  In asthma, it is likely that TSLP, IL-33 and 
IL-25 production by airway epithelial cells conditions DC so that type 2 immune responses 
are enhanced. Further work is needed to examine the relative importance of TSLP, IL-33 and 
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IL-25 across different asthma phenotypes.  Conversely, low dose endotoxin exposure protects 
against experimental asthma via induction of A20 in epithelial cells and inhibition of DC 
recruitment and activation 24. Airway epithelial cells from people with asthma show lower 
expression of A20 than healthy control subjects 24, so it is likely that this effects DC function in 
human asthma, though this has yet to be confirmed.  
In “Th2 high asthma”, greater numbers of airway mucosal CD1c+ cDC express FcεRIα 
than in “Th2 low asthma” 25. Froidure and colleagues recently reported that persistent asthma 
symptoms following a period of allergen avoidance was associated with the extent to which 
cDC were able to promote Th2 cytokine production by CD4 T-cells 26. House dust mite 
allergen upregulates CD141 expression on monocyte derived DC 27. This is significant because 
CD141 expressing DC induce a strongly Th2-polarized cytokine response in naïve 28 and 
memory CD4 T-cells 27, while CD141 expression in blood leukocytes is elevated during acute 
asthma exacerbations 27. 
 
With respect to pDC, a number of reports indicate that lung pDC are recruited to the 
airway lumen following allergen inhalation 14,29, and this is associated with elevated numbers 
of bone marrow pDC 19. There is no consensus in the literature on whether circulating pDC 
numbers differ between adults with asthma and healthy individuals 30,31, though it is likely 
that pDC fluctuate over time in responses to environmental exposures, especially virus 
infections. In a birth cohort study, relative deficiency of circulating pDCs during infancy was 
shown to predict subsequent respiratory tract infections, wheezing, and a diagnosis of asthma 
by the age of 5 years 32. 
 
Asthma is also linked to changes in receptor expression and pDC function. Following 
prolonged allergen avoidance, ongoing asthma symptoms are associated with persistently 
lower pDC expression of the ligand for the regulatory protein known as inducible 
costimulatory molecule (ICOS-L). Blood mononuclear cells from those with asthma generally 
produce less IFNα following viral activation in vitro; this appears to be most evident in those 
with severe asthma 31,33 and airway neutrophilia 34, but may not be seen in milder asthma 35. 
Deficient IFN production by blood leukocytes in asthma is likely to be a consequence of pDC 
dysfunction, though only a few studies have specifically examined purified pDC. Gill and 
colleagues demonstrated that influenza virus stimulated pDC from people with asthma 
produce less IFNα than pDC from healthy individuals, and this was amplified by IgE cross-
linking 36.  Similarly, in children with allergic asthma, FcεRIα expression on pDCs is inversely 
associated with rhinovirus-induced IFN-α and IFN-λ1 production 37. Furthermore, allergen 
inhalation enhances expression of granzyme B in airway pDC 38. 
 
COPD 
It is clear that cigarette smoking per se can lead to increases in the number of lung cDC, 
even in the absence of overt lung disease 39. These cDC show prominent expression of the 
Langerhans’ cell markers langerin and CD1a and the costimulatory molecules CD80 and CD86 
39. The effects of cigarette smoke on DC production of IL-8 and prostaglandin E2 appears to be 
mediated via both oxidative stress and the direct effects of nicotine 40. Lymphoid aggregates 
are a common feature in COPD and these are often infiltrated by langerin + cDC, especially in 
those with severe airflow obstruction 41. Higher costimulatory molecule expression on lung 
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cDC has also been linked to disease severity 42. The small airways in COPD contain cDC with 
heightened expression of chemokine ligand 20 (CCL20), a potential cause of CD8 T-cell 
activation 43. In contrast, there is evidence that some aspects of cDC function may be down 
regulated in COPD with cDC immaturity associated with airway vascularity and expression of 
angiogenic factors 44, and reduced expression of the chemokine receptor CCR5 45. 
Furthermore, a recent report indicates that CD1c+ DCs from patients with COPD hinder T-cell 
effector functions and favor the generation of suppressive T cells. The authors speculate that 
these features of cDC might contribute to impaired immunity to respiratory viruses 46. Though 
these observations may seem contradictory, they are consistent with the notion that COPD is 
characterized by a paradoxical combination of heightened inflammatory responses that 
contribute to tissue damage and reduced host defence against respiratory pathogens. There is 
a need for more research into the role that DC populations might play in disease progression 
and COPD exacerbations. 
 
Microbes 
There is considerable interest in the way that DC respond to respiratory microbes, 
both pathogens and commensal organisms. Larsen and colleagues recently compared the 
effects of airway commensals and pathogenic bacteria on human monocyte derived DC, 
reporting that pathogenic bacteria provoke considerably higher IL-23, IL-12p70 and IL-10 
production than commensal bacteria such as Prevotella spp. and Veillonella spp 47. This may 
be a mechanism favouring clearance of pathogens from the lungs versus persistence of 
commensal organisms. In patients with acute pneumonia, blood mDC and pDC numbers are 
markedly reduced, relative to control subjects, probably as a result of their recruitment to 
inflamed lung tissue 48. Expression of Fc gamma receptors was elevated on mDC, while TLR9 
was elevated on pDC 48. In a study of patients with H1N1 influenza pneumonia hospitalized 
during the 2009 influenza pandemic, significant depletion of blood pDC and mDC was 
observed during the acute phase of the disease 49. Interestingly, blood pDC counts remained 
persistently low for up to 16 weeks 49. 
 
Lung Cancer and Mesothelioma 
Most malignant tumors, including lung cancers and mesothelioma, can produce a 
variety of factors that suppress the generation of an efficient anti-tumor immune response as 
summarized recently 50. Nonetheless, there is strong evidence suggests that DC function in 
lung cancer has a major impact on clinical outcomes. In a study of 458 patients with primary 
lung carcinoma, a high density of mature DC (i.e. those highly expressing lysosomal associated 
membrane protein-3) within tertiary lymphoid structures in tumors was significantly and 
independently associated with improved long-term survival 51. Conversely, DC isolated from 
non-small cell lung tumors can over express immuno-regulatory molecules such as PD-L1 52 
and CD276 (a member of the B7 family also known as B7-H3) 53 and these are likely to be 
associated with a poor prognosis. Lung cancers can secrete galectin-1 that enhances DC 
production of heparin binding EGF-like growth factor which then increases cancer 
progression 54.  There is much interest in utilizing DC-based vaccines in combination with 
activated killer T-cells to enhance the host anti-tumor response in lung cancer. Though some 
early studies have shown promising results in patients with surgically resected non-small cell 
lung cancer 55, confirmation in large multi centre studies are needed.  
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The way forward – research and potential therapies 
Even though many of the initial studies of human lung DC relied on surgical resection 
specimens and lung biopsies, recent years have seen improved methods for identifying and 
characterizing DC in the circulation, sputum, and BAL of patients with lung diseases. These 
relatively less invasive methods make serial measurements of DC and longitudinal studies 
much more feasible. Much research on human DC until now has involved small, cross-
sectional observational studies. While these have some value, there is a need for more 
sophisticated approaches that will allow us to better identify features of DC biology that 
predict important clinical outcomes, and that might be therapeutic targets. Such approaches 
might involve experimental challenges with various environmental stimuli, dynamic studies 
of disease exacerbations, and large prospective studies of well-defined patient cohorts.  
DC have profound effects on cell mediated and humoral immunity and the future is 
likely to include new approaches whereby antigens or small molecules    are targeted using 
antibodies to receptors on particular DC subpopulations 56. This is likely to provide efficient 
mechanisms to enhance, suppress or redirect immune responses against particular antigens 
while maintaining host defence and avoiding collateral lung tissue damage.  
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Figure Legend 
 
Figure 1: Dendritic cells integrate information received from inhaled antigen and the local 
tissue, which they transfer together with antigenic peptides to responding T-cells. This has a 
profound effect on the nature of the ensuing T-cell response. 
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